Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference

Stock News

2025/10/27

ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1100490684"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100490684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100490684?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100490684","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference","media":"Stock News","content":"<p>ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-27 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"","article_id":"1100490684","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100490684","pubTimestamp":1761530770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4134":"信息科技咨询与其它服务","III":"信息服务","BK1161":"生物科技","02256":"和誉-B","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"港股动向|2025年ESMO会议公布皮米替尼III期研究数据，和必拓-B(02256)大涨超7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":1,"III":1},"content_text":"ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}